Glaukos Corp (GKOS.N): Palmetto Kicks Off Their LCD Discussion; Broad Support for iDose

Research evidence excerpt

Glaukos Corp (GKOS.N): Palmetto Kicks Off Their LCD Discussion; Broad Support for iDose

Flash |

22 Jun 2026 16:22:41 ET │ 10 pages

Glaukos Corp (GKOS.N)

Palmetto Kicks Off Their LCD Discussion; Broad Support for iDose

CITI’S TAKE

Following the proposed LCD for the anterior segment intraocular non-

Buy biodegradable drug-eluting system (iDose TR, link) published on

Price (22 Jun 26 16:00) US$131.19 5/21/2026, Palmetto hosted public meetings today to solicit feedback. In

both meetings, physicians emphasized the heterogeneity of glaucoma and Target price US$162.00

need for preservation of physician flexibility in choosing a treatment plan Expected share price return 23.5%

based on individual patient needs and considerations. Specifically, Expected dividend yield 0.0%

feedback was for: 1) the removal of the “history of failed SLT” prerequisite; Expected total return 23.5%

2) modification of the “history of failed medical management” Market Cap US$7,705M

requirement; and 3) to allow stacking iDose concomitantly with MIGS

procedures as they are not redundant but complimentary and potentially

reduce the number of times a patient will require surgical intervention. We

are encouraged by the Palmetto meetings and look forward to additional Joanne WuenschAC

MAC meetings later this week, including: 1) WPS on 6/24; 2) NGS on 6/25; +1-212-816-9606

and 3) Noridian on 6/25. We rate GKOS Buy. joanne.wuensch@citi.com

Anthony Occhiogrosso

Proposed LCD restricts options and increases patient burden. Physicians claimed +1-212-816-7579

that the proposed LCD contains guardrails that are “too restrictive too soon,” arguing anthony.occhiogrosso@citi.com

that the treatment must have an opportunity to grow and to develop more data first.